目的比较两种含吉西他滨非小细胞肺癌(NSCLC)化疗方案,吉西他滨(GEM)联合顺铂(DDP)与吉西他滨(GEM)联合奈达铂(NDP),分析其疗效及不良反应(ADR)上的差异,为临床制定个体化给药方案提供参考.方法选择徐州医科大学附属医院2015年1月至2017年4月诊断为中晚期非小细胞肺癌的患者58例,GEM联合NDP方案组(GN方案)30例,GEM联合DDP方案组(GP方案)28例,治疗周期为21天,每次化疗周期记录不良反应,第3次化疗开始前检测肿瘤CT进行疗效评估,开展两方案不良反应及疗效比较.结果GN方案有效率为43.33％,GP方案有效率为42.86％,二者在疗效上无显著性差异(P>0.05);GN方案消化道症状的发生率低于GP方案(P0.05).结论GN方案与GP方案疗效接近,而GN方案的胃肠道反应更轻,且无需水化治疗,耐受性好.从有效性、安全性等考虑,GN方案可作为GP方案替代治疗方案.%Objective To compare the two gemcitabine related chemotherapy regimens (gemcitabine (GEM) in combination with cisplatin (DDP) or nedaplatin(NDP)) on non-small cell lung cancer(NSCLC), analyze the differences of curative effect and adverse drug reactions (ADR), and provide reference to clinical individualized regimen. Methods The 58 cases diagnosed with NSCLC patients in Xuzhou Medical University Affiliated Hospital between January 2015 and April 2017 were divided into 2 groups, 30 cases of NDP combined with GEM (GN), 28 cases of DDP combined with GEM (GP), treatment cycles within 21 days. Recorded ADR of each cycle of chemotherapy regimens; evaluated curative effect using CT when the third cycle chemotherapy had been finished, then analyzed the adverse reactions and curative effect between the two regimens. Results GN regimen effective rate is 43.33％, GP is 42.86％, there is no significant difference (P>0.05). Gastrointestinal symptoms incidences of NP are lower than GP regimens (P0.05). Conclusion Curative effect of GN is similar to GP, and the gastrointestinal reaction of GN is slighter, good tolerance, without hydration treatment. From the effectiveness and safety considerations, GN scheme is comparable with GP for treatment options.
展开▼
